Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $41.08 and traded as high as $48.23. Global X Genomics & Biotechnology ETF shares last traded at $47.81, with a volume of 5,928 shares.

Global X Genomics & Biotechnology ETF Price Performance

The company has a market capitalization of $54.03 million, a price-to-earnings ratio of -20.43 and a beta of 1.22. The stock has a 50-day moving average price of $46.18 and a 200-day moving average price of $41.08.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were given a dividend of $0.5912 per share. The ex-dividend date was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -26.50%.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Several institutional investors have recently made changes to their positions in GNOM. IFP Advisors Inc boosted its stake in Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after purchasing an additional 489 shares during the last quarter. Halbert Hargrove Global Advisors LLC increased its holdings in shares of Global X Genomics & Biotechnology ETF by 182.4% in the second quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock worth $115,000 after purchasing an additional 8,839 shares during the last quarter. Oxinas Partners Wealth Management LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 12.1% in the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock valued at $137,000 after acquiring an additional 1,751 shares during the last quarter. Atria Investments Inc boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 12.6% in the 2nd quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after purchasing an additional 2,073 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after acquiring an additional 4,615 shares during the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.